doi: 10.1186/s40880-017-0254-z

The 150 most important questions in cancer research and clinical oncology series: questions 67–75

Chinese Journal of Cancer1

[Abstract] Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which spark diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 9 more questions are presented as followed. Question 67. How could we overcome the resistance of hepatocellular carcinoma against chemotherapeutics? Question 68. Is pursuit of non-covalent small-molecule binders of RAS proteins viable as a strategy of cancer drug discovery? Question 69. In what oligomeric structures do RAS proteins signal? Question 70. How can we achieve non-invasive early detection and diagnosis of lung cancer? Question 71. Does genetic information influence the volatolome enabling diagnosis of lung cancer with genetic mutations via cell headspace or breath analysis? Question 72. Is heavy ion beam radiotherapy effective to kill cancer stem cells? Question 73. Is there any diversity among different types of cancer in terms of sensitivity to heavy ion beam radiotherapy? Question 74. Can targeted alpha-particle therapy augment the effect of carbon ion radiotherapy on malignancies? Question 75. How does chromosomal instability drive tumor progression?

Chinese Journal of Cancer 2017, Volume: 36, Issue 10

[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)
[Google Scholar]

Cite this article

Chinese Journal of Cancer1. The 150 most important questions in cancer research and clinical oncology series: questions 67–75. Chin J Cancer. 2017, 36:86. doi:10.1186/s40880-017-0254-z


Export citations

EndNote